STOCK TITAN

Veradigm (MDRX) Stock Price, News & Analysis

MDRX OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
34 239 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+12.2% close of April 28, 2026
1-year change
+2% closing prices, November 13, 2025 to November 13, 2026
1-month change
+0% closing prices, October 13, 2026 to November 13, 2026

Company Description

Veradigm Inc. (MDRX) is a healthcare technology company that operates in the computer systems design services industry within the professional, scientific, and technical services sector. According to its public communications, Veradigm focuses on healthcare data and technology solutions that are delivered through a combination of platforms, data assets, connectivity, and specialized expertise. Its shares trade on the over-the-counter market under the symbol MDRX.

The company describes its core environment as the Veradigm Network, which it characterizes as a dynamic community of solutions and partners. Within this network, Veradigm provides advanced insights, technology, and data-driven solutions tailored to the needs of healthcare providers, payer organizations, and biopharmaceutical companies. Across multiple disclosures, Veradigm emphasizes that its mission is "Transforming Health, Insightfully," highlighting a focus on using data and technology to improve healthcare performance and outcomes.

Business focus and solutions

Veradigm identifies itself as a provider of healthcare data and technology solutions that support clinical, operational, and financial performance for its clients. In its statements, the company notes that its solutions are intended to strengthen clinical quality, reduce administrative burdens, and lower healthcare costs for healthcare organizations. Veradigm also highlights offerings that relate to revenue cycle and coding services, clinical data exchange, and payer insights.

In one example involving Syracuse Orthopedic Specialists, Veradigm describes Veradigm Revenue Cycle Services as a healthcare revenue cycle management service that is EHR-agnostic and designed to help lower accounts receivable days, reduce claim errors, and generate fewer denials. The company also references Veradigm Coding Services, which it states integrates with a practice’s electronic health record system to identify deficiencies and optimize coding and claims workflow. Veradigm notes that it collaborates with practices to manage complex exceptions, increase first-pass claims, and expedite revenue generation.

In addition, Veradigm refers to products such as Veradigm Revenue Analytics, Veradigm Practice Management, and Veradigm Payerpath in connection with practice management and revenue-related processes. These references indicate that the company’s offerings extend across analytics, practice management, and payer connectivity for ambulatory and specialty practices.

Data, AI, and real-world evidence

Veradigm frequently emphasizes the role of data and analytics in its business. The company states that it applies artificial intelligence to deidentified electronic health record data within the Veradigm Network to generate real-world evidence, including for GLP-1 receptor agonists. According to its description, this AI-driven curation is used to surface contextual insights such as side effects, reasons for therapy discontinuation, comorbidities, and social determinants of health that are typically embedded in unstructured or semi-structured EHR fields.

Veradigm explains that this approach is intended to support life science organizations, research, regulatory engagement, and value-based decision-making by enabling scalable extraction of clinical signals from large volumes of patient records. The company notes that it pairs AI techniques with clinical validation and that its network captures structured and unstructured data across diverse patient populations and geographies.

Support for value-based care and payer–provider collaboration

In multiple communications, Veradigm highlights its role in value-based care and payer–provider collaboration. The company reports that it received a KLAS Points of Light Award for work described as "Optimizing Value-Based Care by Delivering Insights at the Point of Care." In that case study, Veradigm and a payer organization integrated real-time risk and quality alerts into an ambulatory provider’s electronic health record to improve clinical decision support, reduce provider burnout, and lower costs.

Veradigm states that, through the Veradigm Network and offerings such as Veradigm Payer Insights, it focuses on sharing patient data across key pillars of healthcare via integrated workflows. The company notes that this includes consolidating external insights, incorporating social determinants of health, and using transition-of-care alerts to support better documentation, improved outcomes, and reduced administrative burden.

Engagement with providers, payers, and biopharma

Across its disclosures, Veradigm consistently identifies three primary stakeholder groups: healthcare providers, payer organizations, and biopharmaceutical companies. For providers, the company cites solutions related to practice operations, revenue cycle management, coding, and clinical workflow support. For payers, Veradigm references collaborations to deliver quality and risk insights at the point of care and to support value-based care arrangements. For biopharma and life sciences, it highlights real-world evidence generation and data-driven insights derived from EHR data.

Veradigm also notes that it works with independent provider practices and ambulatory care organizations, and that its tools are used to help capture necessary documentation for conditions relevant to payer programs. The company’s communications describe efforts to reduce friction in workflows, increase transparency into gaps in care, and enable more efficient use of clinical and administrative staff time.

Media, thought leadership, and industry presence

In addition to its technology and data offerings, Veradigm engages in media and thought leadership activities. The company has announced the Smart Medicine Podcast, which it describes as a show aimed at clinicians, healthcare professionals, and payer and life science leaders. According to Veradigm, the podcast features physicians, entrepreneurs, business leaders, and healthcare innovators discussing topics such as value-based care, medical entrepreneurship, point-of-care innovation, workflow management, revenue cycle management, patient and staff engagement, regulation, and the business aspects of healthcare.

Veradigm also references participation in industry events and conferences, including presenting research posters at professional meetings and speaking about collaborations that support value-based care and payer–provider alignment. These activities are positioned by the company as extensions of its mission to use data and technology to improve healthcare delivery and economics.

Capital markets and reporting status

Veradigm’s public statements indicate that its common stock trades under the symbol MDRX on the over-the-counter market. The company has communicated that it is working to become current in its SEC financial filings and has filed an Annual Report on Form 10-K for a prior fiscal year that includes restated financial statements. Veradigm has also discussed efforts to remediate material weaknesses and internal control deficiencies and has stated an intention to apply for relisting of its shares on a national stock exchange after it becomes current in its financial reporting.

In addition, Veradigm has described a stockholder rights plan adopted by its board of directors and later amended to change the triggering threshold and extend the plan’s expiration date. The company has explained that the purpose of the rights plan is to ensure that all stockholders have the opportunity to realize the potential value of their investment and that the plan does not prevent the company from considering offers that its board views as fair and in the interests of stockholders.

Financial disclosures and business segments

In its financial updates, Veradigm presents revenue and other metrics for two primary categories: Provider and Payer & Life Science. These categories are used in the company’s reporting of revenue and non-GAAP measures such as adjusted EBITDA and non-GAAP gross margin. Veradigm has also provided information on cash, debt, and net cash, as well as explanations of non-GAAP financial measures and how management uses them to assess underlying business performance.

While specific financial figures change over time and are not suitable as evergreen content, the repeated use of these categories in company disclosures indicates that Veradigm views provider-focused and payer and life science–focused activities as core elements of its business structure.

Investor communications

Veradigm regularly announces investor conference calls and webcasts to discuss business updates, financial information, and outlooks. The company notes that replays of these calls are made available for extended periods. Through these communications, Veradigm reiterates its focus on its business model, its value proposition based on data and technology, and its efforts to address reporting and control matters while pursuing growth in its core healthcare technology and data activities.

Stock Performance

$5.00
+0.50%
+0.03
Last updated: November 13, 2026 at 16:00
+2%
Performance 1 year
$545.0M

Veradigm (MDRX) closed at $5.00 on November 13, 2026. Over the past 12 months, the price has gained 2.0%.

See what a $1,000 investment in MDRX would be worth today

Average down calculator for MDRX

MDRX Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Veradigm generated $594.4M in revenue in FY2024, retaining a 50.8% gross margin, operating income reached -$194.7M (-32.8% operating margin), and net income was -$291.5M, reflecting a -49.0% net profit margin. Diluted earnings per share stood at -$2.70. The company generated -$20.0M in operating cash flow. The current ratio was 1.29, measuring current assets divided by current liabilities.

$594.4M
Revenue (FY2024)
-$291.5M
Net Income (FY2024)
-$20.0M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for MDRX.

Short Interest History

Last 12 Months

Short interest in Veradigm (MDRX) currently stands at 553.0 thousand shares, down 0.9% from the previous reporting period, representing 0.5% of the float. Since November 2025, short interest has decreased by 16.7%.

Days to Cover History

Last 12 Months

Days to cover for Veradigm (MDRX) currently stands at 1.5 days, down 90.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 69.5%. Across the settlements charted above, it has ranged from 1.0 to 21.4 days.

MDRX Company Profile & Sector Positioning

Veradigm (MDRX) operates in the Health Information Services industry within the broader Healthcare sector and is listed on the OTC.

Investors comparing MDRX often look at related companies in the same sector, including RaySearch Labs AB (RSLBF), Ping An Hlthcre &Tech (PIAHY), Vitalhub Corp COM NO PAR (VHIBF), Hydreight Technolgies Inc (HYDTF), and Renalytix Plc (RNLXY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MDRX's relative position within its industry.

Frequently Asked Questions

The current stock price of Veradigm (MDRX) is $5.00 as of November 13, 2026.

The market cap of Veradigm (MDRX) is approximately $545.0M. Learn more about what market capitalization means .

The FY2024 revenue of Veradigm (MDRX) is $594.4M, from its most recent completed fiscal year.

The FY2024 net income of Veradigm (MDRX) is -$291.5M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Veradigm (MDRX) is -$2.70 for FY2024, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Veradigm (MDRX) is -$20.0M for FY2024, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Veradigm (MDRX) is -49.0% for FY2024, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Veradigm (MDRX) is -32.8% for FY2024, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Veradigm (MDRX) is 50.8% for FY2024, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Veradigm (MDRX), current assets divided by current liabilities, was 1.29 at the end of FY2024, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Veradigm (MDRX) is $302.2M for FY2024, its most recent completed fiscal year.

The operating income of Veradigm (MDRX) is -$194.7M for FY2024, its most recent completed fiscal year. Learn about operating income.

Veradigm Inc. is a healthcare technology company that focuses on healthcare data and technology solutions. Through the Veradigm Network, it offers platforms, data, connectivity, and expertise to deliver advanced insights and data-driven solutions for healthcare providers, payer organizations, and biopharmaceutical companies.

Veradigm states that it serves three main markets: healthcare providers, payers, and biopharma. Its solutions are described as supporting clinical, operational, and financial performance for provider practices, enabling payer–provider collaboration, and generating real-world evidence and insights for life science organizations.

The Veradigm Network is described by the company as a dynamic community of solutions and partners. It brings together platforms, data, connectivity, and expertise to provide advanced insights, technology, and data-driven solutions across the healthcare provider, payer, and biopharma markets.

Veradigm reports that it applies artificial intelligence to deidentified electronic health record data within the Veradigm Network to scale the generation of real-world evidence. This AI-driven curation is used to extract clinical signals from unstructured and semi-structured data, such as side effects, reasons for therapy discontinuation, comorbidities, and social determinants of health.

In its communications, Veradigm highlights solutions such as Veradigm Revenue Cycle Services and Veradigm Coding Services, which it describes as supporting revenue cycle management and coding workflows. It also references Veradigm Revenue Analytics, Veradigm Practice Management, and Veradigm Payerpath in connection with practice management, analytics, and payer connectivity for provider organizations.

Veradigm reports that it collaborates with payers and providers to support value-based care by delivering insights at the point of care. In one case study recognized with a KLAS Points of Light Award, Veradigm and a payer integrated real-time risk and quality alerts into an electronic health record system to help close care gaps, improve clinical decision support, reduce provider burnout, and lower overall healthcare costs.

Veradigm Payer Insights is mentioned by the company as part of its focus on clinical data exchange and payer solutions. According to Veradigm, it is used within the Veradigm Network to share patient data across key pillars of healthcare through integrated workflows, including consolidating external insights and incorporating social determinants of health and transition-of-care alerts.

Veradigm states that Veradigm Revenue Cycle Services is an EHR-agnostic healthcare revenue cycle management service designed to help lower accounts receivable days, reduce claim errors, and generate fewer denials. Veradigm Coding Services is described as integrating with EHR systems to identify deficiencies, optimize coding and claims workflow, manage complex exceptions, and increase first-pass claims to expedite revenue generation.

Veradigm states that its mission is "Transforming Health, Insightfully." In its descriptions, the company links this mission to using its combination of platforms, data, connectivity, and expertise to drive value and provide data-driven solutions that support better healthcare performance and outcomes.

Veradigm has indicated that its common stock trades under the symbol MDRX on the over-the-counter market. The company has reported filing an Annual Report on Form 10-K for a prior year that includes restated financial statements and has stated that it is working to remediate material weaknesses and internal control deficiencies, become current in its financial reporting, and apply for relisting of its shares on a national stock exchange.

Veradigm has disclosed that its board of directors adopted a stockholder rights plan and later approved an amendment to extend its expiration date and change the triggering threshold. The company explains that the rights plan is intended to ensure that all stockholders have the opportunity to realize the potential value of their investment and notes that the plan does not prevent the company from pursuing offers that its board considers fair and in the best interests of stockholders.